Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous spectrum of disorders. In the last few years, neuroimaging has contributed to the phenotypic characterisation of these patients. Complementary to the clinical and neuropsychological evaluations, structural magnetic resonance imaging (MRI) and functional techniques provide important pieces of information for the diagnosis of FTLD. They also appear to be useful in distinguishing FTLD from patients with Alzheimer's disease (AD). Preliminary studies in pathologically proven cases suggested that distinct patterns of tissue loss could assist in predicting in vivo the pathological subtype. Recent years have also witnessed impressive advances in the development of novel imaging approaches. Diffusion tensor MRI and functional MRI have improved our understanding of the pathophysiology of the disease, and this should lead to the identification of additional useful markers of disease progression. This reviews discusses comprehensively the state-of-the-art of neuroimaging in the study of FTLD spectrum of disorders, and attempts to envisage which will be new neuroimaging biomarkers that could serve as surrogate measures of the underlying pathology. This will be central in the design of treatment trials of experimental drugs, which are likely to emerge in the near future, to target the pathological processes associated with this condition.

Original languageEnglish
Pages (from-to)389-413
Number of pages25
JournalCortex
Volume48
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Frontotemporal Lobar Degeneration
Neuroimaging
Magnetic Resonance Imaging
Diffusion Magnetic Resonance Imaging
Pathologic Processes
Disease Progression
Alzheimer Disease
Biomarkers
Pathology
Degeneration
Pharmaceutical Preparations

Keywords

  • Diffusion tensor (DT) MRI
  • Frontotemporal lobar degeneration (FTLD)
  • Functional MRI (fMRI)
  • Positron emission tomography (PET)
  • Structural MRI

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Arts and Humanities (miscellaneous)
  • Developmental and Educational Psychology

Cite this

Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders. / Agosta, Federica; Canu, Elisa; Sarro, Lidia; Comi, Giancarlo; Filippi, Massimo.

In: Cortex, Vol. 48, No. 4, 04.2012, p. 389-413.

Research output: Contribution to journalArticle

@article{596e216ee0ff4ae89eda367db39310bf,
title = "Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders",
abstract = "Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous spectrum of disorders. In the last few years, neuroimaging has contributed to the phenotypic characterisation of these patients. Complementary to the clinical and neuropsychological evaluations, structural magnetic resonance imaging (MRI) and functional techniques provide important pieces of information for the diagnosis of FTLD. They also appear to be useful in distinguishing FTLD from patients with Alzheimer's disease (AD). Preliminary studies in pathologically proven cases suggested that distinct patterns of tissue loss could assist in predicting in vivo the pathological subtype. Recent years have also witnessed impressive advances in the development of novel imaging approaches. Diffusion tensor MRI and functional MRI have improved our understanding of the pathophysiology of the disease, and this should lead to the identification of additional useful markers of disease progression. This reviews discusses comprehensively the state-of-the-art of neuroimaging in the study of FTLD spectrum of disorders, and attempts to envisage which will be new neuroimaging biomarkers that could serve as surrogate measures of the underlying pathology. This will be central in the design of treatment trials of experimental drugs, which are likely to emerge in the near future, to target the pathological processes associated with this condition.",
keywords = "Diffusion tensor (DT) MRI, Frontotemporal lobar degeneration (FTLD), Functional MRI (fMRI), Positron emission tomography (PET), Structural MRI",
author = "Federica Agosta and Elisa Canu and Lidia Sarro and Giancarlo Comi and Massimo Filippi",
year = "2012",
month = "4",
doi = "10.1016/j.cortex.2011.04.012",
language = "English",
volume = "48",
pages = "389--413",
journal = "Cortex",
issn = "0010-9452",
publisher = "Masson SpA",
number = "4",

}

TY - JOUR

T1 - Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders

AU - Agosta, Federica

AU - Canu, Elisa

AU - Sarro, Lidia

AU - Comi, Giancarlo

AU - Filippi, Massimo

PY - 2012/4

Y1 - 2012/4

N2 - Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous spectrum of disorders. In the last few years, neuroimaging has contributed to the phenotypic characterisation of these patients. Complementary to the clinical and neuropsychological evaluations, structural magnetic resonance imaging (MRI) and functional techniques provide important pieces of information for the diagnosis of FTLD. They also appear to be useful in distinguishing FTLD from patients with Alzheimer's disease (AD). Preliminary studies in pathologically proven cases suggested that distinct patterns of tissue loss could assist in predicting in vivo the pathological subtype. Recent years have also witnessed impressive advances in the development of novel imaging approaches. Diffusion tensor MRI and functional MRI have improved our understanding of the pathophysiology of the disease, and this should lead to the identification of additional useful markers of disease progression. This reviews discusses comprehensively the state-of-the-art of neuroimaging in the study of FTLD spectrum of disorders, and attempts to envisage which will be new neuroimaging biomarkers that could serve as surrogate measures of the underlying pathology. This will be central in the design of treatment trials of experimental drugs, which are likely to emerge in the near future, to target the pathological processes associated with this condition.

AB - Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous spectrum of disorders. In the last few years, neuroimaging has contributed to the phenotypic characterisation of these patients. Complementary to the clinical and neuropsychological evaluations, structural magnetic resonance imaging (MRI) and functional techniques provide important pieces of information for the diagnosis of FTLD. They also appear to be useful in distinguishing FTLD from patients with Alzheimer's disease (AD). Preliminary studies in pathologically proven cases suggested that distinct patterns of tissue loss could assist in predicting in vivo the pathological subtype. Recent years have also witnessed impressive advances in the development of novel imaging approaches. Diffusion tensor MRI and functional MRI have improved our understanding of the pathophysiology of the disease, and this should lead to the identification of additional useful markers of disease progression. This reviews discusses comprehensively the state-of-the-art of neuroimaging in the study of FTLD spectrum of disorders, and attempts to envisage which will be new neuroimaging biomarkers that could serve as surrogate measures of the underlying pathology. This will be central in the design of treatment trials of experimental drugs, which are likely to emerge in the near future, to target the pathological processes associated with this condition.

KW - Diffusion tensor (DT) MRI

KW - Frontotemporal lobar degeneration (FTLD)

KW - Functional MRI (fMRI)

KW - Positron emission tomography (PET)

KW - Structural MRI

UR - http://www.scopus.com/inward/record.url?scp=80054889083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054889083&partnerID=8YFLogxK

U2 - 10.1016/j.cortex.2011.04.012

DO - 10.1016/j.cortex.2011.04.012

M3 - Article

C2 - 21632046

AN - SCOPUS:80054889083

VL - 48

SP - 389

EP - 413

JO - Cortex

JF - Cortex

SN - 0010-9452

IS - 4

ER -